Patents by Inventor Vincent Segers

Vincent Segers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROTEASE RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE
    Publication number: 20220009984
    Abstract: The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-I to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair.
    Type: Application
    Filed: September 14, 2020
    Publication date: January 13, 2022
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard T. LEE, Vincent SEGERS
  • PROTEASE RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE
    Publication number: 20210246182
    Abstract: The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-I to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair.
    Type: Application
    Filed: September 14, 2020
    Publication date: August 12, 2021
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard T. LEE, Vincent SEGERS
  • Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
    Patent number: 10774124
    Abstract: The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: September 15, 2020
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard T. Lee, Vincent Segers
  • NEUREGULIN IN THE TREATMENT OF FIBROTIC DISORDERS
    Publication number: 20170333529
    Abstract: The present invention relates to the treatment of fibrotic disorders. More particularly, the present invention relates to the use of a neuregulin protein in a method treating, preventing and/or delaying fibrotic skin disorders, fibrotic lung disorders or liver cirrhosis.
    Type: Application
    Filed: January 20, 2016
    Publication date: November 23, 2017
    Inventors: Zarha VERMEULEN, Vincent SEGERS, Gilles DE KEULENAER
  • Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
    Patent number: 9631005
    Abstract: The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: April 25, 2017
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard T. Lee, Vincent Segers
  • PROTEASE RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE
    Publication number: 20170101451
    Abstract: The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair.
    Type: Application
    Filed: December 9, 2016
    Publication date: April 13, 2017
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard T. LEE, Vincent SEGERS
  • TREATMENT OF NEPHROPATHY
    Publication number: 20170035848
    Abstract: The present invention relates to the treatment of kidney diseases, both acute and chronic. The invention in particular relates to the use of neuregulins for preventing, treating or delaying kidney diseases.
    Type: Application
    Filed: April 15, 2015
    Publication date: February 9, 2017
    Inventors: Gilles DE KEULENAER, Vincent SEGERS, Leni VANDEKERCKHOVE
  • PROTEASE RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE
    Publication number: 20140024595
    Abstract: The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair.
    Type: Application
    Filed: September 27, 2013
    Publication date: January 23, 2014
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard T. LEE, Vincent SEGERS
  • PROTEASE RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE
    Publication number: 20110269685
    Abstract: The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair.
    Type: Application
    Filed: July 1, 2011
    Publication date: November 3, 2011
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard T. Lee, Vincent Segers
  • Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
    Patent number: 7999067
    Abstract: The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair.
    Type: Grant
    Filed: January 6, 2010
    Date of Patent: August 16, 2011
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Richard T. Lee, Vincent Segers
  • PROTEASE RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE
    Publication number: 20100184950
    Abstract: The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair.
    Type: Application
    Filed: January 6, 2010
    Publication date: July 22, 2010
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard T. Lee, Vincent Segers
  • Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
    Patent number: 7696309
    Abstract: The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: April 13, 2010
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Richard Lee, Vincent Segers
  • Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
    Publication number: 20080095758
    Abstract: The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair.
    Type: Application
    Filed: October 19, 2007
    Publication date: April 24, 2008
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Richard Lee, Vincent Segers